Kim, S., Buecher, B., André, T., Jary, M., Bidard, F., Ghiringhelli, F., . . . Borg, C. (2020). Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: A randomized, non-comparative phase II SCARCE GERCOR trial. BMC Cancer.
Citação norma ChicagoKim, Stefano, et al. "Atezolizumab Plus Modified Docetaxel-cisplatin-5-fluorouracil (mDCF) Regimen Versus MDCF in Patients With Metastatic or Unresectable Locally Advanced Recurrent Anal Squamous Cell Carcinoma: A Randomized, Non-comparative Phase II SCARCE GERCOR Trial." BMC Cancer 2020.
Citação norma MLAKim, Stefano, et al. "Atezolizumab Plus Modified Docetaxel-cisplatin-5-fluorouracil (mDCF) Regimen Versus MDCF in Patients With Metastatic or Unresectable Locally Advanced Recurrent Anal Squamous Cell Carcinoma: A Randomized, Non-comparative Phase II SCARCE GERCOR Trial." BMC Cancer 2020.